Phenominer Database Results (23 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
WKY/NCrl water intake drink rate to body weight ratio salidroside (40 mg/kg) (between 1 and 35 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. drinking behavior trait male 140.0 days-175.0 days 6 50.0 ml/d/kg 1.0 2.45 drink intake measuring method 103499 2827
WKY/NCrl diastolic blood pressure salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait male 168.0 days 6 87.0 mmHg 2.0 4.9 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks nighttime measurement 103551 2827
WKY/NCrl acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 90.64 % 2.0 5.29 wire myography 0.0 103591 2827
WKY/NCrl logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 -8.04 null 0.04 0.12 wire myography 0.0 103595 2827
WKY/NCrl body weight salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. body mass male 168.0 days 6 462.0 g 6.0 14.7 body weighing method 0.0 103491 2827
WKY/NCrl diastolic blood pressure salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait male 168.0 days 6 83.0 mmHg 2.0 4.9 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks daytime measurement 103543 2827
WKY/NCrl number of spontaneous locomotor movements per unit time salidroside (40 mg/kg) (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. locomotor behavior trait male 168.0 days 6 1.0 /min 0.1 0.24 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks number of spontaneous locomotor movements per unit time (CMO:0003644) 103575 2827
WKY/NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 98.36 % 0.98 2.59 wire myography 0.0 103599 2827
WKY/NCrl systolic blood pressure salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait male 168.0 days 6 117.0 mmHg 2.0 4.9 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks daytime measurement 103527 2827
WKY/NCrl mesenteric artery phosphorylated eNOS level to total eNOS level ratio salidroside (40 mg/kg) (for 35 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. artery molecular composition trait male 175.0 days 7 0.88 null 0.08 0.21 western blot assay 0.0 103623 2827
WKY/NCrl serum fructosamine level salidroside (40 mg/kg) (for 35 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood fructosamine amount male 175.0 days 6 152.0 umol/l 2.0 4.9 serum fructosamine analysis 0.0 103503 2827
WKY/NCrl blood glucose level salidroside (40 mg/kg) (for 28 days) then fasting (for 16 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood glucose amount male 168.0 days 6 103.0 mg/dl 3.0 7.35 blood glucose test strip read by electrochemical glucometer 0.0 103511 2827
WKY/NCrl systolic blood pressure salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. arterial blood pressure trait male 168.0 days 6 123.0 mmHg 2.0 4.9 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks nighttime measurement 103535 2827
WKY/NCrl heart rate salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. heart pumping trait male 168.0 days 6 334.0 beats/min 3.0 7.35 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks nighttime measurement 103567 2827
WKY/NCrl number of spontaneous locomotor movements per unit time salidroside (40 mg/kg) (between 1 and 28 days) and dark phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. locomotor behavior trait male 168.0 days 6 3.4 /min 0.3 0.73 intra-aortic abdominal radiotelemetry measured 12 hr/night for 4 weeks number of spontaneous locomotor movements per unit time (CMO:0003644) 103583 2827
WKY/NCrl logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 -7.1 null 0.04 0.11 wire myography 103587 2827
WKY/NCrl logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 -8.21 null 0.07 0.19 wire myography 0.0 103611 2827
WKY/NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 90.13 % 1.55 4.1 wire myography 0.0 103615 2827
WKY/NCrl blood glucose level salidroside (40 mg/kg) (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. blood glucose amount male 168.0 days 6 121.0 mg/dl 2.0 4.9 oral glucose tolerance test 0.0 103519 2827
WKY/NCrl heart rate salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. heart pumping trait male 168.0 days 6 284.0 beats/min 4.0 9.8 intra-aortic abdominal radiotelemetry measured 12 hr/day for 4 weeks daytime measurement 103559 2827
WKY/NCrl logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 -7.72 null 0.03 0.08 wire myography 0.0 103603 2827
WKY/NCrl acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel salidroside (40 mg/kg) (for 28 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. vasodilation trait male 168.0 days 7 96.2 % 1.31 3.47 wire myography 0.0 103607 2827
WKY/NCrl aorta wall phosphorylated eNOS level to total eNOS level ratio salidroside (40 mg/kg) (for 35 days) Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. artery molecular composition trait male 175.0 days 7 1.3 null 0.27 0.71 western blot assay 0.0 103619 2827